Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan by Ünal Metin Tokat, Ashkan Adibi, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Get full text

A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer by Jingshu Wang, Xiuping Lai, Herui Yao, Hui Yang, Xiaolong Cao, Xiaochen Wang, Ying Wang, Weiqi Nian, Xiaodong Zheng, Qingxiu Mai, Anding Liu, Xiaozhi Lv, Xiaoying Bi, Junyi Chen, Junyan Wu, Suiwen Ye

“…Abstract Purpose The primary objectives of this trial were aimed at exploring the pharmacokinetic profiles and the human bioequivalence of an intravenous liposomal injection of doxorubicin hydrochloride in comparison with a reference formulation in Chinese patients diagnosed with metastatic breast cancer. Methods To achieve these goals, the trial employed a randomized, open-label, two-formulation crossover dosing strategy among Chinese patients with metastatic breast cancer. …”
Get full text

Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer by Brenno Pastò, Riccardo Vida, Arianna Dri, Lorenzo Foffano, Serena Della Rossa, Lorenzo Gerratana, Fabio Puglisi

Subjects: “…Metastatic breast cancer…”
Get full text

Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial by Jianli Zhao, Yunfang Yu, Wei Ren, Linxiaoxiao Ding, Yongjian Chen, Peng Yuan, Jian Yue, Yaping Yang, Guorong Zou, Tao Chen, Jie Chai, Li Zhang, Wenjing Wu, Yinduo Zeng, Xiujuan Gui, Yangyang Cai, Simin Luo, Zhongyu Yuan, Kang Zhang, Herui Yao, Ying Wang

“…Abstract This multicenter, single‐arm, phase II clinical trial (NCT04034589) evaluated the efficacy and safety of pyrotinib combined with fulvestrant in patients with HR‐positive/HER2‐positive metastatic breast cancer who had experienced trastuzumab treatment failure. …”
Get full text

c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer by Jieun Park, Eun Sol Chang, Ji-Yeon Kim, Chaithanya Chelakkot, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Ji Hye Lee, Jun Young Choi, Na Young Kim, Hyegyeong Lee, Mi-Ran Kang, Mi Jeong Kwon, Young Kee Shin, Yeon Hee Park, Yoon-La Choi

Subjects: “…Metastatic breast cancer…”
Get full text

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre by Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah

“…Methods: We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. …”
Get full text

Correction: c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer by Jieun Park, Eun Sol Chang, Ji-Yeon Kim, Chaithanya Chelakkot, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Ji Hye Lee, Jun Young Choi, Na Young Kim, Hyegyeong Lee, Mi-Ran Kang, Mi Jeong Kwon, Young Kee Shin, Yeon Hee Park, Yoon-La Choi

Get full text

Resolution on the results of scientific-practical conference "Clinical evidence of increasing overall survival in the treatment of metastatic breast cancer", held on 29 November 2014 under the auspices of the Department of health of Moscow by E. T. Bairamov, A. V. Belonogov, V. V. Brusnichkina, A. V. Bulakh, M. Y. Byahov, S. N. Gurov, G. G. Eremeev, N. V. Zhukov, L. G. Zhukova, L. M. Kogonia, P. V. Koposov, L. K. Ovchinnikova, V. V. Radlevich, E. A. Samyshina, A. P. Seryakov, M. D. Ter-Ovanesov, I. E. Shumskaya

“…Objectives: discussion of modern treatment options for metastatic breast cancer (MBC), the determining of the optimal treatment for subgroups of patients with poor prognosis.…”
Get full text

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus by Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi

Subjects: Get full text

Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome by Khaled Abd Elaziz Ahmed Elnaghi, Hosam Ali Alghanmi, Shereef Ahmed Elsamany, Fathia Almarzoki, Mohamed Elsafty, Mohammad Jaffal

Get full text

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer by Ram Patel, John Mathews, Caroline Hamm, Swati Kulkarni, Rasna Gupta, Tarquin Opperman, John Dean Chiong, Abdullah Nasser

Subjects: Get full text

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial by Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, Changping Shan, Xinlan Liu, Yumin Yao, Bing Zhao, Shusen Wang, Xiaohua Zeng, Changlu Hu, Xi Yan, Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, Xinhong Wu, Deyong Zhang, Tong Li

“…The LEONARDA-1, a randomized, double-blind, phase III study, was conducted to evaluate the efficacy and safety of lerociclib in HR+/HER2− locally advanced or metastatic breast cancer patients, who had relapsed or progressed on prior endocrine therapy. …”
Get full text

Time Series measurements of White Blood Cells (WBC) and plasma Cancer Antigen 15-3 (CA 15-3) in a patient with metastatic breast cancer, serving as a reference for assessing the clinical relevance of different clustering algorithms. by Alexandros CLOUVAS

“…In a recent study, the significance of the K-means clustering algorithm was examined for the first time in evaluating time-series measurements of plasma Cancer Antigen 15-3 (CA 15-3) in a male patient with metastatic breast cancer. CA 15-3 is a glycoprotein commonly associated with breast cancer. …”
Get full text

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study by Dinesh Chandra Doval, Tanveer Maksud, Rajnish Nagarkar, Satheesh Chiradoni Thunagappa, Rakesh Taran, Saurabh Prasad, Anoop T. Manoharan, Minish Jain, Dhruv Mehta, Prabrajya Narayan Mohapatra, Sachin Gupta, Kritarth Naman Singh, Aarohan Pruthi, Rohit Arora

Get full text

Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden by Qianying Zuo, Jin Young Yoo, Erik R. Nelson, Matthew J. Sikora, Rebecca B. Riggins, Zeynep Madak-Erdogan

“…Abstract Patients with metastatic breast cancer face reduced quality of life and increased mortality rates, necessitating more effective anti-cancer strategies. …”
Get full text

Potential antiproliferative effect of isoxazolo- and thiazolo coumarin derivatives on breast cancer mediated bone and lung metastases by Ballazhi Lulzime, Popovski Emil, Jashari Ahmed, Imeri Faik, Ibrahimi Ibrahim, Mikhova Bozhana, Mladenovska Kristina

“…The study highlights the current progress in the development of coumarin scaffolds for drug discovery as novel anticancer agents in metastatic breast cancer. Eight compounds, combining the coumarin core and five membered heterocycles (isoxazoles and thiazoles) in hydrazinyldiene- -chroman-2,4-diones, were characterized in terms of a potential antiproliferative effect on bone (SCP1833) and lung (SCP4175) metastatic breast cancer cell lines using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. …”
Get full text

Association of Structural Maintenance of Chromosome-1A Phosphorylation with Progression of Breast Cancer by Sushma Yadav, Claudia M. Kowolik, Daniel Schmolze, Yuan Yuan, Min Lin, Arthur D. Riggs, David A. Horne

“…Immunohistochemical (IHC) staining was conducted using previously validated phospho-SMC1A antibodies on a histological section and tissue microarray (TMA) comprising samples from primary, invasive, and metastatic breast cancer and normal breast tissues. Our results revealed that p-SMC1A staining intensity was lower in normal breast tissues compared to invasive or metastatic breast cancer tissues (<i>p</i> < 0.001). …”
Get full text

Evaluation of the a-amylase enzyme, Carbohydrate Antigen CA-15.3 ( C.A 15.3),and some biochemical variables in the blood serum of breast cancer patients by Nagham abd, Ebtehal Sabri Mohammed, Amer Fadel Dawood

“…The tumor marker (C.A 15.3) is one of the most reliable markers for monitoring metastatic breast cancer. The results obtained from this study indicated that (C.A 15.3) values were high in women with breast cancer in all stages of the disease, and the values were very high especially in the last two stages of the disease. …”
Get full text

Isolated Gastrointestinal Metastasis of Breast Carcinoma: A Case Report by M. A. Titi, A. Anabtawi, A. D. Newland

“…Although more common causes for gastrointestinal symptoms should be excluded, however, a high index of suspicion of metastatic breast cancer is needed when such patients develop gastrointestinal symptoms.…”
Get full text

The Role of Pulmonary Metastasectomy in Breast Cancer with Limited Progression Following CDK4/6 Inhibitor Therapy: A Case Report by Yu-Ting Su, Shang-Hung Chen

“…Metastatic breast cancer is primarily managed with systemic therapy; however, the role of pulmonary metastasectomy (PM) in patients with pulmonary oligometastases remains uncertain. …”
Get full text